Pacira Pharmaceuticals Incorporated
$5.4M 18,305 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Valencia Technologies Corporation
Valencia Technologies Corporation reported $5,395,604.49 across General Payments, Research, and Ownership to 473 physicians and teaching hospitals across 527 transactions.
- $5.4M
- All-tracks total
- 527
- Transactions
- 473
- Recipients
- −$628.7K
- General Payments vs PY2023
Valencia Technologies Corporation reported $5,395,604.49 across all CMS Open Payments tracks (General + Research + Ownership) to 473 physicians and teaching hospitals in Program Year 2024 - ranking #261 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $259,355.59, averaging $11.4K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer valencia-technologies-corporation Valencia Technologies Corporation
$5.4M · #261/1,925 · 0.0% industry · PY2024
- TOT $5.4M
- RANK #261
- SHARE 0.0%
- TXN 527
- RCP 473
- CAT 3
- GEN $259.4K
- ΔGEN −$628.7K
- TOP1 28.1%
- PY 2024
Volume peers
Nearest volume peer: Pacira Pharmaceuticals Incorporated ($5.4M)
Valencia Technologies Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Valencia Technologies Corporation's CMS-reported General Payments decreased by $628.7K (−70.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: VALENCIA TECHNOLOGIES CORPORATIONPY2023: VALENCIA TECHNOLOGIES CORPORATIONPY2024: Valencia Technologies Corporation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $888,041.80
- PY2024
- $259,355.59
What the Data Shows for Valencia Technologies Corporation
In Program Year 2024, Valencia Technologies Corporation reported $5,395,604.49 in payments to 473 physicians and teaching hospitals across 527 individual transactions, an average of $10.2K per transaction and $11.4K per recipient. That total places Valencia Technologies Corporation at rank #261 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
Of the 3 general-payment categories charted below, "Consulting Fee" is the largest at $211.9K across 41 transactions, 81.7% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Valencia Technologies Corporation made 3 types of general payments. "Consulting Fee" is the largest category at $211.9K, 81.7% of General Payments.
How Valencia Technologies Corporation divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $211.9K | 41 | 81.7% |
| Travel and Lodging | $28.3K | 41 | 10.9% |
| Food and Beverage | $19.2K | 391 | 7.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $194,270.67 (74.9%) of $259,355.59 in this company's General Payments records across 201 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Valencia Technologies Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Alexandra Rogers
$72,967.46 across 15 reported transactions
- 2
Jason Michael Kim
$62,233.35 across 26 reported transactions
- 3
Scott Avard Macdiarmid
$26,534.39 across 14 reported transactions
- 4
Caitlin Frances Lim
$20,143.47 across 15 reported transactions
- 5
Subhro Kamal Sen
$12,392.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Valencia Technologies Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Valencia Technologies Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Valencia Technologies Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
KLS-Martin L.P.
$5.3M 6,287 recipients
Compare payment profiles
SpringWorks Therapeutics, Inc.
$5.3M 4,420 recipients
Compare payment profiles
Olympus Corporation of the Americas
$5.2M 4,448 recipients
Compare payment profiles
Mitsubishi Tanabe Pharma America, Inc.
$5.2M 3,683 recipients
Compare payment profiles
BioXcel Therapeutics, Inc.
$5.2M 532 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.